moxifloxacin

Known as: 1-cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid, MOXI 
A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and… (More)
National Institutes of Health

Related topics

Related topics

36 relations
AmiodaroneAmiodarone hydrochlorideAvelox 400 mg oral tablet includes Avelox ABC PackBacterial Infections
(More)

Broader (3)

Anti-Bacterial AgentsFluoroquinolonesTopoisomerase II Inhibitors

Narrower (5)

AveloxMoxifloxacin hydrochlorideOctegraProflox
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
BACKGROUND Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
BACKGROUND Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed. METHODS We… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
BACKGROUND New drugs, but also shorter, better-tolerated regimens are needed to tackle the high global burden of tuberculosis… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial
BACKGROUND Acute exacerbations contribute to the morbidity and mortality associated with chronic obstructive pulmonary disease… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
RATIONALE Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
BACKGROUND New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
BACKGROUND The long duration of the current tuberculosis (TB) treatment is demanding and warrants the development of new drugs… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
BACKGROUND Moxifloxacin is a quinolone antimicrobial that has potent activity against Mycobacterium tuberculosis. To optimize… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
STUDY OBJECTIVES To compare the effectiveness of oral moxifloxacin with standard antibiotic therapy in acute exacerbation of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 4
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.
The pharmacokinetics of moxifloxacin and its metabolites M1 (sulpho-compound) and M2 (acyl-glucuronide) were characterized in 12… (More)
  • figure 1
  • table I
  • table II
  • figure 2
  • figure 3
Is this relevant?